| Biologic and clinical characteristics of adolescent and young adult cancers: Acute lymphoblastic leukemia, colorectal cancer, breast cancer, melanoma, and sarcoma. Tricoli JV, Blair DG, Anders CK, Bleyer WA, Boardman LA, Khan J, Kummar S, Hayes-Lattin B, Hunger SP, Merchant M, Seibel NL, Thurin M, Willman CL. Cancer. (April 2016) 122(7):1017-28. doi: 10.1002/cncr.29871. |
2016 |
| Future perspectives in melanoma research: Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015. Ascierto PA, Agarwala S, Botti G, Cesano A, Ciliberto G, Davies MA, Demaria S, Dummer R, Eggermont AM, Ferrone S, Fu YX, Gajewski TF, Garbe C, Huber V, Khleif S, Krauthammer M, Lo RS, Masucci G, Palmieri G, Postow M, Puzanov I, Silk A, Spranger S, Stroncek DF, Tarhini A, Taube JM, Testori A, Wang E, Wargo JA, Yee C, Zarour H, Zitvogel L, Fox BA, Mozzillo N, Marincola FM, Thurin M. J Transl Med. (November 2016) 14(1):313. PMID: 27846884 |
2016 |
| Nanoproteomic Analysis of ischemia-dependent changes in signaling protein phosphorylation in colorectal normal and cancer tissue. Unger FT, Lange N, Kruger J, Compton C, Moore H, Agrawal L, Juhl H & David KA. J Transl Med. (January 2016) 14(1):6. |
2016 |
| The National Institutes of Health Affordable Cancer Technologies Program: Improving Access to Resource-Appropriate Technologies for Cancer Detection, Diagnosis, Monitoring, and Treatment in Low- and Middle-Income Countries. Pearlman PC, Divi R, Gwede M, Tandon P, Sorg BS, Ossandon MR, Agrawal L, Pai V, Baker H & Lash TB. IEEE J Transl. Engin. in Health and Med. (Sept 2016) 99. |
2016 |
| Plasmid-Based Materials as Multiplex Quality Controls and Calibrators for Clinical Next-Generation Sequencing Assays. Sims DJ, Harrington RD, Polley EC, Forbes TD, Mehaffey MG, McGregor PM, Camalier CE, Harper KN, Bouk CH, Das B, Conley BA, Doroshow JH, Williams PM, Lih CJ. J Mol. Diag. (May 2016) 8:13. |
2016 |
| Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women with Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. Harris, LN, Ismaila N, McShane LM, Andre F, Collyar DE, Gonzalez-Angulo AM, Hammond EH, Kuderer NM, Liu MC, Mennel RG, Poznak C, Bast RC, & Hayes DF. (February 2016) J Clin Oncol 34. |
2016 |
| Validation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validation. Masucci GV, Cesano A, Hawtin R, Janetzki S, Zhang J, Kirsch I, Dobbin KK, Alvarez J, Robbins PB, Selvan SR, Streicher HZ, Butterfield LH, Thurin M. J Immunother Cancer. (November 2016) 4:76. PMID: 27895917 |
2016 |
| Validation of biomarkers to predict response to immunotherapy in cancer: Volume II - clinical validation and regulatory considerations. Dobbin KK, Cesano A, Alvarez J, Hawtin R, Janetzki S, Kirsch I, Masucci GV, Robbins PB, Selvan SR, Streicher HZ, Zhang J, Butterfield LH, Thurin M. J Immunother Cancer. (November 2016) 4:77. doi: 10.1186/s40425-016-0179-0. PMID: 27891226 |
2016 |
| Sparano JA et al. Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. September 28, 2015. The New England Journal of Medicine. |
2015 |
| Greytak SR, Engel KB, Bass BP, Moore HM. Accuracy of Molecular Data Generated with FFPE Biospecimens: Lessons from the Literature. Cancer Res. 2015 Apr 2 (Epub ahead of print) |
2015 |
| Bass BP, Engel KB, Greytak SR, Moore HM. A Review of Preanalytical Factors Affecting Molecular, Protein, and Morphological Analysis of Formalin-Fixed, Paraffin-Embedded (FFPE) Tissue: How Well Do You Know Your FFPE Specimen? Arch Pathol Lab Med. 2014 Nov;138(11):1520-30. |
2014 |
| Magdalena Thurin and Francesco M Marincola (Eds.), 2014 Molecular Diagnostics for Melanoma, Book (1st edition), New York, NY, Springer Science, 712 pp, Print. |
2014 |
| Luke JJ et al. Biology of advanced uveal melanoma and next steps for clinical therapeutics. Pigment Cell Melanoma Res. 2014 Aug 12. |
2014 |
| Lee JA, Biel NM, Kozikowski RT, Siemann DW, Sorg BS. In vivo spectral and fluorescence microscopy comparison of microvascular function after treatment with OXi4503, Sunitinib and their combination in Caki-2 tumors. Biomed Opt Express. Jun 1, 2014; 5(6): 1965–1979. |
2014 |
| Hall JA, Salgado R, Lively T, Sweep F, Schuh A. A risk-management approach for effective integration of biomarkers in clinical trials: perspectives of an NCI, NCRI, and EORTC working group. Lancet Oncol. 2014 Apr;15(4):e184-93 |
2014 |
| Parkinson DR, McCormack RT, Keating SM, Gutman SI, Hamilton SR, Mansfield EA, Piper MA, Deverka P, Frueh FW, Jessup JM, McShane LM, Tunis SR, Sigman CC, Kelloff GJ. Evidence of clinical utility: an unmet need in molecular diagnostics for patients with can |
2014 |
| Ascierto PA et al. Future perspectives in melanoma research: report from the ‘Melanoma Bridge’ meeting, Napoli, December 5th-8th 2013. J Transl Med. 2014;12(1):277 |
2013 |
| Conley BA, Abrams JS, McShane LM. Statistical and Practical Considerations for Clinical Evaluation of Predictive Biomarkers. J Natl Cancer Inst (2013) doi: 10.1093/jnci/djt282 First published online: October 17, 2013 |
2013 |
| McShane LM, Polley MY. Development of omics-based clinical tests for prognosis and therapy selection: the challenge of achieving statistical robustness and clinical utility. Clin Trials. 2013 Oct;10(5):653-65 |
2013 |
| McShane L, Cavenagh M, Lively T, Eberhard D, Bigbee W, Williams M, et al. Criteria for the use of omics-based predictors in clinical trials. Nature. 2013; 502: 317 - 20. |
2013 |
| McShane L, Cavenagh M, Lively T, Eberhard D, Bigbee W, Williams P, et al. Criteria for the use of omics-based predictors in clinical trials: explanation and elaboration. BMC medicine. 2013; 11(1): 220 |
2013 |
| F. Betsou et al., Identification of Evidence-Based Biospecimen Quality-Control Tools: A Report of the International Society for Biological and Environmental Repositories (ISBER) Biospecimen Science Working Group. The Journal of molecular diagnostics : JMD 15, 3 (Jan, 2013). |
2013 |
| N. Mucci et al., Meeting Research Needs with Postmortem Biospecimen Donation: Summary of Recommendations for Postmortem Recovery of Normal Human Biospecimens for Research. Biopreserv Biobank in press, (2013). |
2013 |
| Future perspectives in melanoma research. Meeting report from the “Melanoma Bridge. Napoli, December 2nd-4th 2012.” Ascierto PA, Grimaldi AM, Acquavella N, Borgognoni L, Calabrò L, Cascinelli N, Cesano A, Del Vecchio M, Eggermont AM, Faries M, Ferrone S, Fox BA, Gajewski TF, Galon J, Gnjatic S, Gogas H, Kashani-Sabet M, Kaufman HL, Larkin J, Lo RS, Mantovani A, Margolin K, Melief C, McArthur G, Palmieri G, Puzanov I, Ribas A, Seliger B, Sosman J, Suenaert P, Tarhini AA, Trinchieri G, Vidal-Vanaclocha F, Wang E, Ciliberto G, Mozzillo N, Marincola FM, Thurin M. J Transl Med. 2013 Jun 3;11:137. doi: 10.1186/1479-5876-11-137. |
2012 |
| D. G. Altman, L. M. McShane, W. Sauerbrei, S. E. Taube, Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): explanation and elaboration. PLoS medicine 9, e1001216 (2012). |
2012 |
| R. Chuaqui, A. Rasooly, in Biosensors for Cancer Detection and Diagnostics, A. Rasooly, Ed. (Taylor & Francis, London, 2012). |
2012 |
| J. Galon et al., Cancer classification using the Immunoscore: a worldwide task force. Journal of translational medicine 10, 205 (Oct 3, 2012). |
2012 |
| J. Galon et al., The Immune Score as a New Possible Approach for the Classification of Cancer. Journal of translational medicine 10, (Jan 3, 2012). |
2012 |
| D. Groelz et al., Non-formalin fixative versus formalin-fixed tissue: A comparison of histology and RNA quality. Experimental and molecular pathology 94, 188 (Jul 17, 2012). |
2012 |
| S. Lehman et al., Standard Preanalytical Coding for Biospecimens: Review and implementation of the Sample PREanalytical Code (SPREC). Biopreservation and Biobanking 10, 366 (2012). |
2012 |
| N. C. Lockhart, R. Yassin, C. J. Weil, C. C. Compton, Intersection of biobanking and clinical care: should discrepant diagnoses and pathological findings be returned to research participants? Genetics in medicine : official journal of the American College of Medical Genetics 14, 417 (Apr, 2012). |
2012 |
| C. Mathay et al., Short-term stability study of RNA at room temperature. Biopreserv Biobank 10, 532 (2012). |
2012 |
| L. M. McShane, Statistical challenges in the development and evaluation of marker-based clinical tests. BMC medicine 10, 52 (2012). |
2012 |
| L. M. McShane, D. F. Hayes, Publication of tumor marker research results: the necessity for complete and transparent reporting. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 30, 4223 (Dec 1, 2012). |
2012 |
| S. Meshinchi, S. P. Hunger, R. Aplenc, P. C. Adamson, J. M. Jessup, Lessons learned from the investigational device exemption review of Children's Oncology Group trial AAML1031. Clinical cancer research : an official journal of the American Association for Cancer Research 18, 1547 (Mar 15, 2012). |
2012 |
| H. M. Moore, The NCI Biospecimen Research Network. Biotechnic & histochemistry : official publication of the Biological Stain Commission 87, 18 (Jan, 2012). |
2012 |
| G. Poste et al., Leveling the playing field: bringing development of biomarkers and molecular diagnostics up to the standards for drug development. Clinical cancer research : an official journal of the American Association for Cancer Research 18, 1515 (Mar 15, 2012). |
2012 |
| Y. R. Rubinstein et al., Informed consent process for patient participation in rare disease registries linked to biorepositories. Contemporary clinical trials 33, 5 (Jan, 2012). |
2012 |
| R. L. Schilsky, J. H. Doroshow, M. Leblanc, B. A. Conley, Development and use of integral assays in clinical trials. Clinical cancer research : an official journal of the American Association for Cancer Research 18, 1540 (Mar 15, 2012). |
2012 |
| J. Vaught, N. C. Lockhart, The evolution of biobanking best practices. Clin Chim Acta 413, 1569 (Oct 9, 2012). |
2012 |
| J. B. Vaught, M. K. Henderson, C. C. Compton, Biospecimens and biorepositories: from afterthought to science. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 21, 253 (Feb, 2012). |
2012 |
| P. M. Williams, T. G. Lively, J. M. Jessup, B. A. Conley, Bridging the gap: moving predictive and prognostic assays from research to clinical use. Clinical cancer research : an official journal of the American Association for Cancer Research 18, 1531 (Mar 15, 2012). |
2012 |
| R. Yassin, C. Weil, N. Lockhart, Sharing individual research results with biospecimen contributors: point. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 21, 256 (Feb, 2012). |
2012 |
| F. Andre et al., Biomarker studies: a call for a comprehensive biomarker study registry. Nature reviews. Clinical oncology 8, 171 (Mar, 2011). |
2011 |
| L. H. Butterfield et al., Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers. Clinical Cancer Research 17, 3064 (May 15, 2011). |
2011 |
| M. Dowsett et al., Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. Journal of the National Cancer Institute 103, 1656 (Nov 16, 2011). |
2011 |
| K. B. Engel, H. M. Moore, Effects of preanalytical variables on the detection of proteins by immunohistochemistry in formalin-fixed, paraffin-embedded tissue. Archives of pathology & laboratory medicine 135, 537 (May, 2011). |
2011 |
| G. Hallmans, J. B. Vaught, Best practices for establishing a biobank. Methods Mol Biol 675, 241 (2011). |
2011 |
| V. L. Keedy et al., American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 29, 2121 (May 20, 2011). |
2011 |
| H. Moore et al., Biospecimen Reporting for Improved Study Quality. Biopreservation and Biobanking 9, 57 (March 2011, 2011). |
2011 |
| H. M. Moore, C. C. Compton, J. Alper, J. B. Vaught, International approaches to advancing biospecimen science. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 20, 729 (May, 2011). |
2011 |
| J. Rogers, T. Carolin, J. Vaught, C. Compton, Biobankonomics: a taxonomy for evaluating the economic benefits of standardized centralized human biobanking for translational research. Journal of the National Cancer Institute. Monographs 2011, 32 (2011). |
2011 |
| J. V. Tricoli, N. L. Seibel, D. G. Blair, K. Albritton, B. Hayes-Lattin, Unique characteristics of adolescent and young adult acute lymphoblastic leukemia, breast cancer, and colon cancer. Journal of the National Cancer Institute 103, 628 (Apr 20, 2011). |
2011 |
| J. Vaught, M. K. Henderson, in Molecular Epidemiology: Principles and Practices, N. Rothman, et al., Ed. (International Agency for Research on Cancer Press, 2011). |
2011 |
| J. Vaught, J. Rogers, T. Carolin, C. Compton, Biobankonomics: developing a sustainable business model approach for the formation of a human tissue biobank. Journal of the National Cancer Institute. Monographs 2011, 24 (2011). |
2011 |
| J. Vaught et al., An NCI perspective on creating sustainable biospecimen resources. Journal of the National Cancer Institute. Monographs 2011, 1 (2011). |
2011 |
| Butterfield LH, et al. Recommendations from the iSBTc/FDA/NCI Workshop on Immunotherapy Biomarkers. Clin Cancer Res 2011:17;3064-76. |
2011 |
| Taube SE, Clark GM, Dancey JE, McShane LM, Sigman CC, Gutman SI. A perspective on challenges and issues in biomarker development and drug and biomarker codevelopment. J Natl Cancer Inst 2009:101;1453-63. |
2009 |
| Tahara H, et al. Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Markers in Oncology. J Transl Med 2009:7;45. |
2009 |
| Ambs S, Marincola FM, Thurin M. Profiling of immune response to guide cancer diagnosis prognosis and prediction to therapy--meeting report. Cancer Res 2008:68;4031-33. |
2008 |
| Butterfield LH, et al.A systematic approach to biomarker discovery; preamble to the iSBTc-FDA taskforce on immunotherapy biomarkers. J Transl Med 2008:6;81. |
2008 |
